Stephen R. Davis net worth and biography

Stephen Davis Biography and Net Worth

Stephen R. Davis has served as our Chief Executive Officer and a member of our board of directors since 2015. Mr. Davis joined Acadia in July 2014 as Executive Vice President, Chief Financial Officer and Chief Business Officer. He was appointed Interim Chief Executive Officer in March 2015 and named President and Chief Executive Officer in September 2015. Mr. Davis brings over 25 years of executive-level experience in the pharmaceutical industry and more than 25 years of experience on the boards of directors of publicly held biopharmaceutical companies. Previously, Mr. Davis served as Executive Vice President and Chief Operating Officer at Heron Therapeutics, Inc., Executive Vice President and Chief Operating Officer at Ardea Biosciences, Inc., and in numerous executive roles at Neurogen Corporation, including Chief Executive Officer. Mr. Davis currently serves on the Board of Directors of Bellicum Pharmaceuticals, Inc. and Heron Therapeutics. He also recently served on the boards of directors of Synageva BioPharma Corp. and Furiex Pharmaceuticals, Inc. Early in his career, Mr. Davis practiced as a Certified Public Accountant with a major accounting firm and as a corporate and securities attorney with a Wall Street law firm. Mr. Davis received his Bachelor of Science degree in Accounting from Southern Nazarene University and a J.D. from Vanderbilt University.

What is Stephen R. Davis' net worth?: The estimated net worth of Stephen R. Davis is at least $3.18 million as of August 19th, 2024. Mr. Davis owns 186,555 shares of ACADIA Pharmaceuticals stock worth more than $3,184,494 as of March 28th. This net worth approximation does not reflect any other investments that Mr. Davis may own. Additionally, Mr. Davis receives a salary of $1,460,000.00 as CEO at ACADIA Pharmaceuticals. Learn More about Stephen R. Davis' net worth.
How old is Stephen R. Davis?: Mr. Davis is currently 63 years old. There are 5 older executives and no younger executives at ACADIA Pharmaceuticals. Learn More on Stephen R. Davis' age.
What is Stephen R. Davis' salary?: As the CEO of ACADIA Pharmaceuticals Inc., Mr. Davis earns $1,460,000.00 per year. Learn More on Stephen R. Davis' salary.
How do I contact Stephen R. Davis?: The corporate mailing address for Mr. Davis and other ACADIA Pharmaceuticals executives is 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130. ACADIA Pharmaceuticals can also be reached via phone at (858) 558-2871 and via email at ir@acadia-pharm.com. Learn More on Stephen R. Davis' contact information.
Has Stephen R. Davis been buying or selling shares of ACADIA Pharmaceuticals?: Stephen R. Davis has not been actively trading shares of ACADIA Pharmaceuticals during the past quarter. Most recently, Stephen Davis sold 31,747 shares of the business's stock in a transaction on Monday, August 19th. The shares were sold at an average price of $15.28, for a transaction totalling $485,094.16. Following the completion of the sale, the chief executive officer now directly owns 186,555 shares of the company's stock, valued at $2,850,560.40. Learn More on Stephen R. Davis' trading history.
Who are ACADIA Pharmaceuticals' active insiders?: ACADIA Pharmaceuticals' insider roster includes Laura Brege (Director), Stephen Davis (CEO), Elizabeth Garofalo (Director), James Kihara (Insider), Austin Kim (EVP), Elena Ridloff (CFO), Mark Schneyer (CFO), Srdjan Stankovic (President), and Brendan Teehan (COO). Learn More on ACADIA Pharmaceuticals' active insiders.
Are insiders buying or selling shares of ACADIA Pharmaceuticals?: During the last year, insiders at the biopharmaceutical company sold shares 20 times. They sold a total of 140,464 shares worth more than $2,331,351.11. The most recent insider tranaction occured on March, 26th when insider James Kihara sold 1,095 shares worth more than $18,669.75. Insiders at ACADIA Pharmaceuticals own 28.3% of the company. Learn More about insider trades at ACADIA Pharmaceuticals.
Information on this page was last updated on 3/26/2025.

Stephen R. Davis Insider Trading History at ACADIA Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/19/2024	Sell	31,747	$15.28	$485,094.16	186,555
5/2/2024	Sell	11,427	$16.94	$193,573.38	155,231
4/8/2024	Sell	26,574	$17.87	$474,877.38	144,267
3/27/2024	Sell	17,714	$17.90	$317,080.60	118,842
2/26/2024	Sell	5,577	$24.67	$137,584.59	101,890
1/8/2024	Sell	3,732	$29.96	$111,810.72	96,521
10/6/2023	Sell	51,563	$21.96	$1,132,323.48	89,131
7/14/2023	Sell	100,000	$30.04	$3,004,000.00	36,695
7/11/2023	Sell	16,498	$25.00	$412,450.00	91,799
5/1/2023	Sell	7,806	$21.18	$165,331.08	108,297
4/6/2023	Sell	8,582	$18.16	$155,849.12	100,478
2/24/2023	Sell	3,851	$18.78	$72,321.78	91,727
1/9/2023	Sell	3,904	$17.13	$66,875.52	84,633
10/15/2022	Sell	2,804	$15.81	$44,331.24	79,009
5/2/2022	Sell	5,483	$18.18	$99,680.94	75,875
2/23/2022	Sell	3,928	$23.80	$93,486.40
10/18/2021	Sell	2,963	$17.41	$51,585.83
4/30/2021	Sell	7,850	$20.33	$159,590.50
2/4/2021	Sell	14,195	$50.61	$718,408.95	43,059
1/6/2021	Sell	3,484	$53.34	$185,836.56
10/16/2020	Sell	2,960	$42.56	$125,977.60	17,746
5/13/2020	Sell	111,458	$46.35	$5,166,078.30	123,267
4/30/2020	Sell	6,770	$49.21	$333,151.70	18,579
12/5/2019	Sell	150,000	$52.34	$7,851,000.00	152,954
10/15/2019	Sell	2,983	$39.65	$118,275.95	5,937
10/9/2019	Sell	29,792	$40.00	$1,191,680.00	29,792

See Full Table

Stephen R. Davis Buying and Selling Activity at ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Company Overview

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Today's Range

Now: $17.07

$16.92

$17.22

50 Day Range

MA: $18.35

$16.77

$20.37

2 Week Range

Now: $17.07

$14.15

$20.68

Volume

872,103 shs

Average Volume

1,822,158 shs

Market Capitalization

$2.85 billion

P/E Ratio

21.88

Dividend Yield

N/A

Beta

0.43

Stephen Davis Biography and Net Worth

What is Stephen R. Davis' net worth?

How old is Stephen R. Davis?

What is Stephen R. Davis' salary?

How do I contact Stephen R. Davis?

Has Stephen R. Davis been buying or selling shares of ACADIA Pharmaceuticals?

Who are ACADIA Pharmaceuticals' active insiders?

Are insiders buying or selling shares of ACADIA Pharmaceuticals?